cardiogenic shock

in review 7 min read Updated 2026-10-29
cardiogenic shock

Cardiac failure → sustained tissue hypoperfusion (clinical + biochemical), with or without hypotension. Stage by SCAI (A–E), phenotype by ventricle (LV / RV / biventricular). ECG + echo in every patient: ischaemia → cath lab for culprit-only revascularisation; mechanical cause → fix it. Norepinephrine first if hypotensive; inotrope for low output; decongest. Call the shock centre early. No routine IABP or ECMO; microaxial pump only in selected STEMI shock. Short-term mortality 30–40%.

cardiogenic shock — first-hour bundle
  • 12-lead ECG now; ST elevation or ongoing ischaemia → emergency angiography, culprit-only PCI
  • TTE or POCUS: LV/RV function, regional wall motion, tamponade, acute MR, VSR, severe AS
  • arterial line; central line for CVP and ScvO₂
  • labs: lactate, VBG/ABG, CBC, Cr, LFTs, hs-troponin, NT-proBNP, Na⁺, K⁺, Mg²⁺, INR
  • hypotensive: norepinephrine first; MAP target 60–65 mmHg
  • low output with adequate MAP: dobutamine or milrinone (milrinone accumulates in renal failure)
  • avoid dopamine and phenylephrine alone
  • congested: IV loop diuretic ± thiazide → ultrafiltration if refractory
  • stop beta-blocker, ACEi/ARNI, MRA and SGLT2i while in shock
  • stage severity (SCAI B–E) and phenotype (LV, RV or biventricular) and reassess lactate and organs every 2–4 h
  • inferior STEMI with clear lungs and hypotension: RV infarct — no nitrates; small fluid bolus only if RAP is low
  • call the regional shock centre early: refractory shock, ≥1 vasoactive, tMCS being considered, or uncertain neurology after arrest
  • no routine IABP or VA-ECMO; microaxial pump only for selected LV-dominant STEMI shock at an experienced centre
  • early goals-of-care discussion; palliative care if no exit strategy

physiology

  • downward spiral: ↓ cardiac output → ↓ BP → ↓ coronary perfusion → more ischaemia → ↓ output; compensatory vasoconstriction ↑ afterload → further ↓ output
  • congestion injures organs too: high CVP ↓ renal perfusion pressure (MAP − CVP) and congests liver and gut → decongestion is part of resuscitation, not an afterthought
  • late SIRS-like vasodilation → mixed cardiogenic + distributive shock
  • normotensive shock (hypoperfusion with preserved BP from vasoconstriction) has high mortality — BP alone misses it
  • every vasoactive drug raises myocardial O₂ demand and arrhythmia risk → lowest dose, shortest time

recognise

Suspect with any of: SBP <90 or MAP <60–65 for >30 min (or >30 mmHg drop, or needing drugs/devices to hold SBP ≥90), HR >100, narrow pulse pressure (<25% of SBP).

domainfindings
perfusion — clinicalconfusion, cold clammy extremities, capillary refill >2 s, urine <30 mL/h (<0.5 mL/kg/h); nausea, abdominal pain (gut ischaemia)
perfusion — labslactate >2 mmol/L, ALT >200 U/L, creatinine ≥2× ULN, pH <7.2, metabolic acidosis
congestion↑ JVP, crackles, orthopnoea, oedema — clarify LV vs RV vs both
ECGischaemia/STEMI → cath lab
echo / POCUSLV or RV dilation and dysfunction, regional WMA, tamponade, acute MR, VSR, severe AS

Also: hs-troponin, NT-proBNP, Na⁺, VBG/ABG, CBC; arterial line; central line (CVP, ScvO₂).

Causes: AMI (STEMI or NSTEMI, incl. mechanical complications) · HF-CS — acute-on-chronic cardiomyopathy or de novo (myocarditis, Takotsubo, peripartum, tachycardia-mediated) · secondary — valve lesions, tamponade, brady/tachyarrhythmia, LVOT obstruction (HCM, Takotsubo)


SCAI stages

stagepicturetypical markers
A — at risklarge MI, ADHF; perfusing wellnormal lactate, warm
B — beginninghypotension or tachycardia without hypoperfusionSBP <90 or HR ≥100; lactate <2
C — classichypoperfusion needing 1 drug or device beyond fluidlactate ≥2, creatinine ×1.5, UO <30 mL/h, cold
D — deterioratingfailing initial support; escalating to ≥2 drugs/devicelactate ≥4 and rising, worsening organs
E — extremiscirculatory collapse, CPR, ≥3 drugs/deviceslactate ≥8, pH <7.2
  • add arrest modifier (A) if cardiac arrest
  • most patients change stage within 24 h; stage B patients deteriorate most often → reassess lactate and organ function every 2–4 h early

phenotype

LV-dominantRV-dominantbiventricular
haemodynamicsPCWP >15RAP >15 with normal PCWP; RA:PCWP >0.6; low PAPiboth ↑
bedsidepulmonary oedema↑ JVP, clear lungs, hepatic congestionboth
causesanterior MI, cardiomyopathyinferior/RV MI, PE, pulmonary hypertensionadvanced HF, large MI
fluidharmfulsmall bolus only if RAP low; overfilling worsens LV filling (septal shift)harmful
  • PA catheter not mandatory for diagnosis; observational data favour early complete haemodynamic profiling to guide escalation
  • PEEP: ↓ LV afterload and preload → helps LV failure; ↑ PVR → harms RV failure

management

flowchart LR
    A[Suspected CS<br/>hypoperfusion ± hypotension] --> B[ECG + echo/POCUS<br/>lactate, art line<br/>SCAI stage]
    B --> C{Acute MI?}
    C -->|yes| D[Cath lab now<br/>culprit-only PCI]
    C -->|no| E{Mechanical or<br/>reversible cause?}
    E -->|tamponade, acute MR/VSR,<br/>severe AS, arrhythmia| F[Drain / surgery / TAVI /<br/>cardiovert or pace]
    E -->|no| G[HF-CS]
    D --> H{MAP <65?}
    G --> H
    H -->|yes| I[Norepinephrine]
    H -->|no, low output,<br/>high SVR| J[Dobutamine or milrinone]
    I --> K[Add inotrope if<br/>low output persists]
    J --> L[Decongest:<br/>IV loop ± thiazide → UF]
    K --> L
    L --> M{SCAI D/E or<br/>worsening?}
    M -->|yes| N[Shock centre:<br/>tMCS by LV/RV/BiV<br/>bridge to recovery,<br/>LVAD or transplant]
    M -->|no| O[Reassess q2–4 h<br/>de-escalate early]

first hour

  • ECG + echo; STEMI or ongoing ischaemia → emergency angiography regardless of time from symptom onset
  • shock team activation (where available); contact the regional shock centre as soon as CS is confirmed — refractory AMI-CS after local PCI, ≥1 vasoactive, tMCS being considered or uncertain neurological status after arrest → discuss transfer
  • MAP target 60–65 mmHg
  • early goals-of-care discussion; palliative care if no exit strategy (recovery, durable LVAD, transplant)

vasoactives

  • norepinephrine first for hypotensive CS (ESC IIb; ACC consensus)
  • dobutamine or milrinone for low output once MAP adequate, or in normotensive CS with high SVR; no difference in outcomes — DOREMI (2021); milrinone accumulates in renal failure and vasodilates
  • avoid: dopamine (more arrhythmia; ↑ mortality in the CS subgroup of SOAP II (2010)), phenylephrine alone (↑ afterload, reflex bradycardia, ↓ output), epinephrine as first line
  • inotropes not routine in hypotension without hypoperfusion (ESC III)
  • dosing and receptor profiles → vasoactive drugs

temporary mechanical circulatory support (tMCS)

  • no routine use — selected patients at experienced centres
  • IABP: no mortality benefit in AMI-CS — IABP-SHOCK II (2012) (ESC III routine post-MI); may bridge in non-ACS CS or mechanical complications (VSR, acute MR)
  • VA-ECMO: no 30-day benefit when used early in AMI-CS — ECLS-SHOCK (2023); raises LV afterload → often needs LV vent; reserved for SCAI D–E, BiV failure, fulminant myocarditis
  • microaxial flow pump (Impella) in STEMI-CS: ↓ 180-day mortality (absolute 12.7%) — DanGer Shock (2024); selected LV-dominant STEMI shock — SCAI C–E, not comatose after arrest, no RV failure, vessels able to take large-bore access (ACC/AHA 2a); cost = bleeding, limb ischaemia, RRT
  • RV-dominant → percutaneous RV support; BiV → VA-ECMO ± LV vent
  • complications: major bleeding up to 60% in AMI-CS, limb ischaemia (×4 with tMCS) → minimise anticoagulation and access duration
  • no device RCTs in HF-CS

AMI-CS specifics

  • culprit-only PCI at index procedure — multivessel PCI ↑ death or RRT at 30 days in CULPRIT-SHOCK (2017); CABG if anatomy unsuitable
  • new murmur + sudden shock days 1–7 → VSR or papillary muscle rupture → echo → surgery, IABP/MCS bridge
  • inferior STEMI + hypotension + clear lungs → RV infarct: avoid nitrates; small fluid bolus only if RAP low
  • details → STEMI management, acute coronary syndromes, post-cardiac arrest care

HF-CS specifics

  • acute-on-chronic: congestion and renal failure dominate → inotrope + decongestion (IV loop ± thiazide → ultrafiltration)
  • stop beta-blocker, ACEi/ARNI/MRA while shocked; SGLT2i paused; restart GDMT once off support → acute decompensated heart failure
  • de novo: look for myocarditis (consider biopsy), Takotsubo with LVOTO (no inotropes or IABP — fluid if not congested, short-acting beta-blocker, Impella), peripartum

Prepared 2026-10-29. Not yet verified — check every number against the sources.

Key references

+6 more sources

Suggest a correction cardiogenic shock